Accessibility Menu
Lakefront Biotherapeutics logo

Lakefront Biotherapeutics(NASDAQ) LKFT

Market Cap$1.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)+263%
5 Year-52%
1 Year-9%
1 Month+5%
Premium Feature
Moneyball Superscore
45/100
$28.49
-1.35%
-0.39Today
After hours$28.54+$0.05 (+0.18%)
Lakefront Biotherapeutics last closing stock price
MetricPriceDate
Last closeUSD 28.502026-08-31
Lakefront Biotherapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.86%USD 29.042026-08-24
1 month+4.74%USD 27.212026-07-31
3 month+4.51%USD 27.272026-06-02
Year to date-12.84%USD 32.702025-12-31
1 year-9.35%USD 31.442025-08-29
3 year-25.12%USD 38.062023-09-01
5 year-51.78%USD 59.102021-09-01
Since inception+263.06%USD 7.852008-07-07

Lakefront Biotherapeutics Financials at a Glance

Market Cap

$1.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€990.58M

Net Income (TTM)

€596.64M

EPS (TTM)

$10.52

P/E Ratio

2.71

Dividend

$0.00

Beta (Volatility)

0.60 (Low)

Price

$28.49

Volume

133,480.672

Open

$28.59

Previous Close

$28.50

Daily Range

$28.28 - $28.59

52-Week Range

$25.68 - $37.78

Estimated Earnings Date

Nov 12, 2026

LKFT News

GettyImages-944545988

Why Galapagos Trounced the Market Today

Eric VolkmanJan 27, 2022
investor-looking-at-charts-getty

Here's Why Galapagos Stock Is Falling Today

Cory RenauerJul 15, 2021
life-science-professionals

Is Galapagos Stock a Bad-News Buy Right Now?

Cory RenauerFeb 23, 2021
Thumb down

Why Galapagos Stock Is Crashing Today

Keith SpeightsAug 19, 2020
1-2-3-going-up

3 Biotech Stocks With Big Incoming Catalysts

Cory RenauerJul 25, 2020
GettyImages-506712062

Better Buy: Vertex Pharmaceuticals vs. Galapagos

Zhiyuan SunJul 2, 2020
confused-businessman-getty

Galapagos and Gilead Sciences Post Successful Yet Disappointing Filgotinib Results

Cory RenauerMay 21, 2020
GettyImages-187921657

Is Galapagos Stock a Buy?

David HaenApr 12, 2020
Page 1

LKFT: Motley Fool Moneyball Superscore

45

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lakefront Biotherapeutics

Lakefront Biotherapeutics N.V. is a biotechnology company focused on the discovery and development of innovative small molecule and antibody-based therapeutics. The company is actively engaged in clinical development programs targeting various diseases, including idiopathic pulmonary fibrosis.

Products and Services
  • Development of novel small molecule therapeutics
  • Advancement of antibody-based therapies
  • Clinical programs targeting idiopathic pulmonary fibrosis
Growth Outlook
  • Recent quarterly revenue increased to €12.12 million
  • Strong cash position with €1.34 billion in cash and short-term investments
  • Low debt levels support future growth initiatives
Financial Highlights
  • Trailing twelve months (TTM) revenue of €64.81 million
  • Net income of €2.11 million reported in the latest quarter
  • Current ratio of 32.82 indicates strong liquidity
Lakefront Biotherapeutics N.V. has demonstrated a solid financial foundation, with a current ratio significantly above 1, indicating ample liquidity to cover short-term obligations. The company reported a net income of €2.11 million in the most recent quarter, showcasing its ability to generate profit amidst ongoing investments in research and development. The TTM revenue of €64.81 million reflects a growing demand for its innovative therapeutic solutions. With a robust cash position of €1.34 billion, Lakefront Biotherapeutics is well-positioned to pursue further growth opportunities and expand its clinical programs. The low debt levels further enhance its financial stability, allowing for strategic investments in future projects.
AI Generated • Aug 19, 2026

Industry

Biotechnology

Sector

Health Care

Employees

196

CEO

Henry O. Gosebruch, CPA

Website

www.galapagos.com

Headquarters

Mechelen, 2800, BE

LKFT Financials

Key Financial Metrics (TTM)

Gross Margin

94.88%

Operating Margin

61.57%

Net Income Margin

60.23%

Return on Equity

19.58%

Return on Capital

15.46%

Return on Assets

17.81%

Earnings Yield

36.90%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

65.66M

Volume

133.48K

Avg. Volume

208.16K

Financials (TTM)

Gross Profit

€939.84M

Operating Income

€609.93M

EBITDA

€541.60M

Operating Cash Flow

-€192.82M

Capital Expenditure

-€4.58M

Free Cash Flow

-€197.40M

Cash & ST Invst.

€2.24B

Total Debt

€6.36M

Lakefront Biotherapeutics Performance Analysis

Lakefront Biotherapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 253,546,503-55.8%
20232023-12-31EUR 259,169,3572.2%
20242024-12-31EUR 298,166,97515.0%
20252025-12-31EUR 1,255,258,568321.0%
Lakefront Biotherapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-309.0%
Q42025-12-311165.9%
Q12026-03-31-99.3%
Q22026-06-3087.0%
Lakefront Biotherapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -3.4954.1%
20232023-12-31EUR 3.47N/A
20242024-12-31EUR 1.22-65.0%
20252025-12-31EUR 5.50351.9%
Lakefront Biotherapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-91.9%
Q42025-12-31486.6%
Q12026-03-31-98.1%
Q22026-06-30-87.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€12.12M

-81.4%

Gross Profit

-€22.52M

-137.2%

Gross Margin

-1.86%

N/A

Market Cap

$1.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.14M

N/A

Employees

452

N/A

Net Income

€2.11M

+102.0%

EBITDA

-€35.27M

+65.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€2.24B

-27.6%

Total Debt

€6.36M

-24.7%

Accounts Receivable

€56.27M

-35.9%

Inventory

€0.00

-100.0%

Long Term Debt

€4.77M

-21.1%

Short Term Debt

€1.59M

-33.6%

Return on Assets

17.81%

N/A

Return on Invested Capital

18.60%

N/A

Free Cash Flow

€0.00

+100.0%

Operating Cash Flow

€0.00

+100.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About LKFT

What is the current price of Lakefront Biotherapeutics?

Lakefront Biotherapeutics is trading at $28.50 per share.

What is the 52-week range for Lakefront Biotherapeutics?

Over the past 52 weeks, Lakefront Biotherapeutics has traded between $25.68 and $37.78.

How much debt does Lakefront Biotherapeutics have?

As of the most recent reporting period, Lakefront Biotherapeutics reported total debt of €7.27M.

How much cash does Lakefront Biotherapeutics have on hand?

Lakefront Biotherapeutics reported €155.43M in cash and cash equivalents in its most recent financial results.

What is Lakefront Biotherapeutics’s dividend yield?

Lakefront Biotherapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services